Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time. The online post-test and evaluation can be accessed at https://tinyurl.com/AtopicVideo17.
Inquiries about CME accreditation may be directed to the University of Louisville Office of Continuing Medical Education & Professional Development (CME & PD) at firstname.lastname@example.org
Joint Provider Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Global Academy for Medical Education, LLC. The University of Louisville is accredited by the ACCME to provide continuing medical education for physicians.
The University of Louisville Office of Continuing Medical Education & Professional Development designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education: Postgraduate Institute for Medicine is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. This educational activity for 1.0 contact hour(s) is provided by the Postgraduate Institute for Medicine. Designated for 0.1 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
This activity is intended for dermatologists, pediatricians, family practitioners, internists, nurses, nurse practitioners, physician assistants, and other clinicians who treat patients with atopic dermatitis (AD).
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease that is associated with significant morbidity. Symptoms of AD, including erythema and pruritus, along with common comorbidities such as sleep and mood disturbances, can significantly affect the quality of life for patients and their families. Concern about potential adverse effects of steroids can mean that AD is often undertreated. As emerging science continues to reveal the underlying pathophysiology of AD, new steroid-sparing topical and systemic treatments are being developed to target the immunological mechanisms that produce characteristic AD symptoms. Clinicians need to be familiar with the safety and efficacy data relevant to the use of current and emerging therapies. Clinicians also need to be prepared to counsel families about comprehensive approach for managing AD and for preventing flares, including effective skin hygiene and proper application of adequate doses of topical preparations.
By viewing and studying this activity, participants should be better able to:
• Discuss the immunodulatory pathways that contribute to atopic dermatitis (AD) symptomatology
• Design strategies for proactive management of AD
• Consider the safety and efficacy data for new and emerging agents when designing a course of therapy for atopic dermatitis
• Counsel patients about the role of food allergy in atopic dermatitis (AD)
Address common AD comorbidities, including sleep and mood disturbances
Individuals in a position to control the content of this educational activity are required to disclose: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.
Lawrence F. Eichenfield, MD: Consultant (*past consultant): Novan, Inc.; *Steifel, a GSK Company; Valeant Pharmaceuticals. Investigator: Cassiopea; Galderma Laboratories, L.P.; Novan, Inc.; Steifel, a GSK Company; Valeant Pharmaceuticals.
Jonathan I. Silverberg, MD, PhD, MPH: Consultant: AbbVie; Anacor Pharmaceuticals, Inc.; Galderma Laboratories; GlaxoSmithKline; Lilly, Medimmune-AstraZeneca; Pfizer Inc; Proctor & Gambel; Puricore; Regeneron-Sanofi. Advisory board member: Anacor Pharmaceuticals, Inc. Investigator: AbbVie; Celgene; Chugai; GlaxoSmithKline; Lilly; PuriCore; F. Hoffman-La Roche Ltd.; Speakers bureau: Regeneron-Sanofi.
Wynnis L. Tom, MD: Investigator: Celgene Corporation; Janssen Pharmaceuticals, Inc.; Promius Pharma.
Staff and Advisory Board Disclosures: The University of Louisville CME & PD staff and Advisory Board have nothing to disclose.
CME/CE Reviewers: Cindy England Owen, MD, Assistant Professor, Division of Dermatology, University of Louisville School of Medicine, has no relevant financial relationships to disclose. The PIM planners and managers, Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi SmelkerMitchek, MBA, MSN, RN; and Jan Schultz, MSN, RN, CHCP, have nothing to disclose.
Global Academy for Medical Education Staff: Sylvia H. Reitman, MBA, DipEd; Shirley Jones, MBA; and Ron Schaumburg have no relevant financial relationships to disclose.
Off-Label/Investigational Use Disclosure
This CME/CE activity discusses the off-label use of certain approved medications as well as data from clinical trials on investigational agents. Any such material is identified within the presentations.
The faculty acknowledge the editorial assistance of Global Academy for Medical Education in the development of this activity. The ideas and opinions expressed in it are those of the faculty and do not necessarily reflect the views of the supporter, Global Academy for Medical Education, the University of Louisville, or Postgraduate Institute for Medicine.
Copyright © 2017 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this activity may be reproduced or transmitted in any form, by any means, without prior written permission. Global Academy for Medical Education, LLC, Global Education Group, and Frontline Medical Communications will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this activity, including any claims related to the products, drugs, or services mentioned herein.